Please assess the completion status of the following clinical trial:

Trial Title: Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Sickle cell disease (HbSS or S/β0 thalassemia)~* ≥ 3 vaso-occlusive pain episodes in the year prior to enrollment~* Age ≥ 10 years~* Weight \> 30 kg~Exclusion Criteria:~* Creatine kinase (CK) \> UNL~* Total cholesterol \< 90 mg/dL, or triglycerides \<30mg/dL~* Renal dysfunction (Creatinine \> 1.5-fold UNL)~* Hepatic dysfunction (ALT \> 2-fold UNL)~* Treatment with drugs having known metabolic interactions with statins within the past 30 days~* Vaso-occlusive pain requiring hospitalization within past 30 days~* Red blood cell transfusion within the past 30 days~* Pregnancy/lactation~* Musculoskeletal disorder associated with an elevated CK level~* Past or present history of substance abuse (alcohol, cocaine, amphetamines, heroin)~* Chronic pain caused by avascular necrosis of the bone (AVN) or leg ulcers, and pain due to trauma or causes other than SCD.~* Major cognitive or neurological impairments that may hamper the ability to use the smartphone or complete the electronic pain diary in this study

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- simvastatin (Type: EXPERIMENTAL): Simvastatin (Zocor), 40mg tablet, 40mg orally once daily, for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).